Want to see NAUT full AI Analyst Report?
NAUT Stock Chart & Stats
$3.03
$0.07(3.48%)
At close: 4:00 PM EST
$3.03
$0.07(3.48%)
Day’s Range― - ―
52-Week Range$0.62 - $4.31
Previous CloseN/A
Volume21.91K
Average Volume (3M)394.63K
Market Cap
$233.83M
Enterprise Value$291.28M
Total Cash (Recent Filing)$95.87M
Total Debt (Recent Filing)$28.87M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 04, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding127,078,860
10 Day Avg. Volume378,207
30 Day Avg. Volume394,629
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-95.06
Enterprise Value/Ebitda-5.74
Forecast
1Y Price Target
$4.00Price Target Upside32.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$700.00K
Bulls Say, Bears Say
Bulls Say
Differentiated Proteomics PlatformNautilus's ability to generate proteoform-level, single-molecule data that collaborators could not access previously creates a durable scientific moat. This differentiation supports high-value partnerships, publications, and training of proprietary AI models, strengthening long-term demand for its instruments, assays, and consumables.
Verified Service Lab And Assay ValidationFormal verification/validation of the service lab and Tau assay materially de-risks commercialization. Reproducible, publication-quality outputs are essential for academic and pharma adoption, enabling repeatable revenue from services and building credibility necessary to sell instruments and recurring consumables over time.
Conservative Balance Sheet And Cost DisciplineA sizable cash balance combined with demonstrated OpEx reductions gives Nautilus a multi-quarter runway to reach commercialization milestones without immediate financing. This reduces near-term dilution risk and provides time to complete validation and early commercial deployments, supporting a patient build-out of sales capabilities.
Bears Say
No Revenue And Sustained Cash BurnPersistent zero revenue and large negative operating cash flows indicate the business remains pre-commercial and capital reliant. Continued cash burn erodes equity and forces reliance on external funding or dilution if commercialization is delayed, constraining long-term investment in scale and market expansion.
Nascent Commercial PipelineA very small sales team and a single named early access customer show commercial traction is still unproven. Limited customer references and light commercial coverage lengthen sales cycles, slow recurring consumable uptake, and increase execution risk when scaling to address broader pharma and academic markets.
Technical And Timing Risks To Broadscale LaunchOutstanding verification/validation tasks and collaborator reagent delays introduce meaningful timing and execution risk. Delays to broadscale readiness push revenue realization later, extend cash runway needs, and can weaken adoption momentum, making long-term commercial forecasts highly dependent on successful technical delivery.
Nautilus Biotechnolgy News
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $0.62 and its highest was $4.31 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $233.83M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Aug 04, 2026 which is in 33 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Apr 28, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.145 by $0.025.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.14.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 127,078,860 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.145. Following the earnings report the stock price went up 0.778%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Currently, no hedge funds are holding shares in NAUT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nautilus Biotechnolgy Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (32.01% Upside)
$4.00 (32.01% Upside)
Insider Transactions
Sold Shares
Worth $11.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.20%
12-Months-Change
Fundamentals
Return on Equity
-35.04%
Trailing 12-Months
Asset Growth
-21.92%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
NAUT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantive technical and commercial progress: verified service lab, strong scientific collaborator results (including novel ApoE–Tau proteoform findings), nearly tripled qualified probes, targeted oncology assay progress, and deliberate commercial hires. Financially the company reduced operating expenses YoY and exited the quarter with $143.4M in cash and a stated runway through 2027. Offsetting these positives are external delays (Middle East conflict) that pushed grant revenue recognition and some reagent development later in the year, a nascent sales pipeline with only one named EAP customer so far, remaining verification/validation work before broadscale customer deployments, and modest expected revenue (~$0.5M) for 2026. On balance, accomplishments materially outweigh the challenges but execution and timing risks remain.View all NAUT earnings summariesNAUT Stock 12 Month Forecast
Average Price Target
$4.00
▲(32.01% Upside)
Technical Analysis
Ownership Overview
45.26% Insiders
2.79% Mutual Funds
34.95% Other Institutional Investors
13.52% Public Companies and
Individual Investors